Concepedia

Author

Murray Stewart

GlaxoSmithKline (United States)

Also Known As

James M Swain, James Swain, M Stewart, M W Stewart, M. STEWART, M. Stewart, M. W. Stewart, M.  W.  Stewart, M.W. Stewart, MURRAY STEWART

91

Publications

6.4K

Citations

36

H-Index

79

Concepts

All Affiliations

GlaxoSmithKline (United States)GlaxoSmithKline (United Kingdom)Newcastle UniversityResearch Triangle Park FoundationRhythm (United states)
MS

About

Murray Stewart is an author at GlaxoSmithKline (United States) specializing in medicine, diabetes, and metabolic syndrome.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

17

17

2.9K

2

Health Sciences

7

7

321

3

Public Health

4

4

95

4

Biochemistry

2

2

76

5

Anatomy

1

1

85

Murray Stewart

×

52

Publications

5.4K

Citations

33

H-Index

YearCitations

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Adrian F. Hernandez, Jennifer B. Green, Salim Janmohamed,

The Lancet

2018

1.7K

Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study

Richard E. Pratley, Michael A. Nauck, Anthony Barnett,

The Lancet Diabetes & Endocrinology

2014

319

Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes

Julio Rosenstock, Jane E.B. Reusch, Mark Bush,

Diabetes Care

2009

233

HARMONY 3: 104-Week Randomized, Double-Blind, Placebo- and Active-Controlled Trial Assessing the Efficacy and Safety of Albiglutide Compared With Placebo, Sitagliptin, and Glimepiride in Patients With Type 2 Diabetes Taking Metformin

Bo Åhrén, Susan Johnson, Murray Stewart,

Diabetes Care

2014

222

Advancing Basal Insulin Replacement in Type 2 Diabetes Inadequately Controlled With Insulin Glargine Plus Oral Agents: A Comparison of Adding Albiglutide, a Weekly GLP-1 Receptor Agonist, Versus Thrice-Daily Prandial Insulin Lispro

Julio Rosenstock, Vivian Fonseca, Jorge Luiz Gross,

Diabetes Care

2014

202

Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Albiglutide, a Long-Acting Glucagon-Like Peptide-1 Mimetic, in Patients with Type 2 Diabetes

Jessica Matthews, Murray Stewart, Erika H. De Boever,

The Journal of Clinical Endocrinology & Metabolism

2008

196

Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long‐acting glucagon‐like peptide‐1 mimetic, in healthy subjects

Mark Bush, Jessica Matthews, Erika H. De Boever,

Diabetes Obesity and Metabolism

2009

177

HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea

Peter N. Weissman, Molly C. Carr, June Ye,

Diabetologia

2014

130

Speech and swallow rehabilitation in head and neck cancer: United Kingdom National Multidisciplinary Guidelines

Paul A. Clarke, Kate Radford, Margaret Coffey,

The Journal of Laryngology & Otology

2016

129

Effect of setmelanotide, a melanocortin‐4 receptor agonist, on obesity in <scp>Bardet‐Biedl</scp> syndrome

Robert Haws, Sheila M. Brady, Elisabeth K. Davis,

Diabetes Obesity and Metabolism

2020

125

Page 1